Fins Neuro (1-516-478-8304)
  • Home
  • About Us
  • Contact Us
  • News
  • Denomics
Clinical Resources

Steven H. Rauchman, MD

Contact:dr.rauchman@yahoo.com | 818-264–6735 | www.linkedin.com/in/steven-rauchman-md/GeneralOphthalmologist and ophthalmic surgeon with extensive experience in comprehensive medical and surgical practice. Principal investigator in nationwide pharmaceutical clinical trials, communicating with large pharmaceutical companies on both research and business levels. Cultivates personal and business relationships with Clinical Research Organizations (CROs), a conduit for FDA authorized pharmaceutical trials. Possesses detailed understanding and ensures strict adherence to government regulatory requirements. Assembles and manages a team of clinical staff to execute trials on drugs in development. Establishes and maintains a medical/legal partnership with large law firms, testifies in trials, and is a recognized expert in the ophthalmologic manifestations of Traumatic Brain Injuries (TBI). Reviews articles before publication for a peer-reviewed neuroscience journal.
AREAS OF EXPERTISE
Comprehensive OphthalmologyPharmaceutical Clinical InvestigationMedical Devise Development & PatentingCataract SurgeryStrategic Growth – Medical PracticeBusiness LeadershipTeam BuildingPublic Speaking PROFESSIONAL EXPERIENCENorth Valley Eye Medical Group, Mission Hills, CA January 1987 – December 2020EYE PHYSICIAN | MANAGING PARTNERClinician | Surgeon | Business Leader• Examined an average of 50 patients daily in a 7K sq. ft. ophthalmology suite and managed 30+ employees.• Performed state-of-the-art cataract surgery in a large multi-specialty surgery center.• Liaised between limited partners and large publicly traded national medical corporations.• Directly involved in the employee life cycle for private practice, all HR decisions, and maintained frequent contact with contract HR attorney.• Managed a predominantly bilingual staff with an 80% retention rate who served a mostly minority medical patient base; serviced Medi- Cal contracts to provide care to patients with varying ethnicities and socioeconomic backgrounds.• Negotiated large, managed care contracts with nationally recognized healthcare providers.• Spearheaded business initiatives to launch a long-term strategy of incorporating clinical trials into medical practice to improve financial vitality as well as participated in groundbreaking medical research.• Created medical/legal statewide networks for personal injury evaluations to improve patient access to medical services after eye injuries or TBIs. • Partnered with a nationally recognized organic chemist, Merrill Goldenberg, and hold dual ownership of several patents related to an extended-release platform in glaucoma therapy.• Peer-reviewed the article: The Progress of Label-free Optical Imaging in Alzheimer’s Disease Screening and Diagnosis that was accepted for publication in the journal “Frontiers on Aging Neuroscience”.Clinical Trials• Principal Investigator (PI) or Sub-Investigator for hundreds of Phase Il, Ill, and IV clinical trials on the full spectrum of eye disease and surgery including glaucoma, diabetes, dry eye, cataracts, and presbyopia.• Developed a nationally recognized site for clinical trial investigations. Led site patient enrollment and stayed competitive with other nationally recognized clinical sites.• Collaborated with national leaders in clinical trial development.• Provided medical monitoring of 50+ patient subjects per trial.• Realized income of $1.2M in clinical trial revenue in 2019.• Clinical site noted by FDA to have no deficiencies during clinical site audits for FDA approved medication.• Recent publication in Correspondence section of Nature, recognized as a most prestigious international science journal, regarding clinical trials and COVID, June 2021: COVID: treatment trials are still urgent.• Principal investigator of ongoing multi-institutional retrospective clinical study related to COVID.Medical-Legal Expert• Provided expert medical care for patients with eye trauma and TBI.• Wrote complex medical/legal reports including product liability associated with eye injuries; participated in extensive deposition and trial experience.• Authored extensive blogs with over 50 articles related to ophthalmic manifestations of TBI.• Participated in trauma panel for emergency rooms at a regional trauma center and hospital for 30+ years.• Collaborated with personal injury attorneys with head injuries clients ranging from an eye injury, chemical spill, facial fracture to an accident. Provided quantifiable treatments and recovery estimations based on the extent of the injury.• Trained internal staff to understand medical-legal cases to facilitate discussions with each attorney and their staff.
PUBLICATIONS AND PATENTSPublications:COVID: treatment trials are still urgent: Author Steven Rauchman, M.D. Nature June 2021.Korenfeld MS, Robertson SM, Stein JM, Evans DG, Rauchman SH, Sall KN, Venkataraman S, Chen BL, Wuttke M, Burns W. Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial. Eye (Lond). 2021 Jan 29. doi: 10.1038/s41433-020-01391-z. Epub ahead of print. PMID: 33514891.Comprehensive Eye Exams for Personal Injury Clients. Author Steven Rauchman, M.D. The Advocate Magazine August 2014.A Patient Preference Comparison of Azarga vs. Cosopt in Patients with Open-Angle Glaucoma or Ocular Hypertension. Authors TK Mundorf, SH Rauchman, RD Williams, R. Notivol & Brinzolamide/Timolol Preference Study Group. Clinical Ophthalmolou, Volume 2, Number 3, September 2008s.Indications for Selected Medical and Surgical Procedures, a Literature Review and Ratings Appropriateness. Coronary Angiography. Authors, M.R. Chassin, et al, including S. Rauchman. Editor, A. Fink; Santa Monica, Rand Corporation, 1986.Indications for Selected Medical and Surgical Procedures, a Literature Review and Ratings Appropriateness. Coronary Artery Bypass Graft Surgery. Authors, M.R. Chassin, et al, including S. Rauchman. Editor, A. Fink; Santa Monica, Rand Corporation, 1986.Patent:Goldenberg, Merrill, and Steven H. Rauchman. Self-Retaining Implantable Drug Delivery Device. 27 Aug. 2020.COMMUNITY ACTIVITIESEye Care America | VolunteerConcern Foundation for Cancer Research | MemberSurgical Eye Expeditions, International Mission to El Salvador | Board MemberPROFESSIONAL ORGANIZATIONSAmerican Academy of Ophthalmology | FellowAmerican Society of Cataract and Refractive Surgeons | MemberAssociation for Research in Vision and Ophthalmology | MemberLos Angeles County Medical Association | MemberCalifornia Medical Association | MemberEDUCATION AND CERTIFICATIONSDiplomate American Board of Ophthalmology CertificationBoston University, Boston, MAResidency, OphthalmologyUniversity of Southern CaliforniaLos Angeles County Medical Center, Internship – OphthalmologyUniversity of California, San Francisco, San Francisco, CADoctor of Medicine, M.D. | Regent ScholarUniversity of California, Berkeley, Berkeley, CABachelor of Arts, Psychology | Graduated with Highest Honors | Phi Beta Kappa
Fresno Institute Of Neuroscience
Enhancing NeuroScience Care through Collaboration and Diligence
Services
  • Clinical Neurology Care
  • Neurophysiology Services
  • Research
  • Education
  • Consulting
  • Manuscript Preparation
Location
Headquarters 1558 E Shadow Creek Dr Fresno, Ca 93730
NOTICE TO PATIENTSMedical doctors are licensed and regulated by the Medical Board of California. To check up on a license or to file a complaint go to www.mbc.ca.gov, email licensecheck@mbc.ca.gov, or call (800) 633-2322.
Contact
1-516-478-8304 Phone/Fax/Text
Email: admin@finsneuro.org (secure)
Notice to Patients: The Open Payments database is a federal tool used to search payments made by drug and device companies to physicians and teaching hospitals. It can be found at https://openpaymentsdata.cms.gov.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.

We use cookies to enable essential functionality on our website, and analyze website traffic. By clicking Accept you consent to our use of cookies. Read about how we use cookies.

Your Cookie Settings

We use cookies to enable essential functionality on our website, and analyze website traffic. Read about how we use cookies.

Cookie Categories
Essential

These cookies are strictly necessary to provide you with services available through our websites. You cannot refuse these cookies without impacting how our websites function. You can block or delete them by changing your browser settings, as described under the heading "Managing cookies" in the Privacy and Cookies Policy.

Analytics

These cookies collect information that is used in aggregate form to help us understand how our websites are being used or how effective our marketing campaigns are.